Még nem toboroz
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
NCT07247786· 2. fázis· Fundación GECP· Forrás
Toboroz
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
NCT06716021· 3. fázis· Milestone Pharmaceuticals Inc.· Forrás
Toboroz
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
2024-519836-18-00· 3. fázis· Newron Pharmaceuticals S.p.A.· Forrás
Toboroz
Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-
Negative Adult Subjects with Chronic Hepatitis B (B-SUPREME)
2025-521178-33-00· 2. fázis· Aligos Therapeutics Inc.· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain.
2025-521152-34-00· 2. fázis· Astrazeneca Farmaceutica Spain S.A.· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· 3. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
NCT07001800· 2/3. fázis· Kardigan, Inc.· Forrás
Toboroz
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
NCT06431633· 3. fázis· Fundación GECP· Forrás
Meghívásos bevonás
Effectiveness of Home-Based Exercise and Brain Stimulation for Reducing Fatigue in Patients With Multiple Sclerosis
NCT07567989· Jacobo Formigo· Forrás
Toboroz
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis (SchizOMICS)
NCT06060886· 4. fázis· Consorcio Centro De Investigacion Biomedica En Red· Forrás
Toboroz
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
NCT06435429· 3. fázis· Jazz Pharmaceuticals Ireland Limited· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325· 3. fázis· UCB Biopharma SRL· Forrás
Toboroz
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
NCT06634199· Fundación GECP· Forrás
Contact: Martín Lazaro, MD
Fut, nem toboroz
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249· 4. fázis· GlaxoSmithKline· Forrás
Toboroz
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935· 3. fázis· Janssen-Cilag Ltd.· Forrás
Toboroz
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· 3. fázis· Institut Gustave Roussy· Forrás
Fut, nem toboroz
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· 3. fázis· Summit Therapeutics· Forrás
Fut, nem toboroz
Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy
NCT05952206· 3. fázis· iVascular S.L.U.· Forrás
Toboroz
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717· 2/3. fázis· GlaxoSmithKline· Forrás
Meghívásos bevonás
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441· 3. fázis· argenx· Forrás
Fut, nem toboroz
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
NCT05810870· 2. fázis· MedSIR· Forrás
Toboroz
Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence after surgery
2024-517666-41-00· 3. fázis· Instituto De Investigacion En Oncología Radioterapica FEOR· Forrás
Fut, nem toboroz
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin)- unresponsive non-muscle invasive bladder cancer (NMIBC) patients.
2024-518486-10-00· 2. fázis· Associacio Per A La Recerca Oncologica· Forrás
Toboroz
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· 3. fázis· Anthos Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095· 3. fázis· Janssen-Cilag Ltd.· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study)
2023-507372-42-00· 2. fázis· Oryzon Genomics S.A.· Forrás
Meghívásos bevonás
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322· 3. fázis· UCB Biopharma SRL· Forrás
Meghívásos bevonás
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506· 2/3. fázis· Cytokinetics· Forrás
Toboroz
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
NCT04752774· 1/2. fázis· Ipsen· Forrás
Fut, nem toboroz
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
NCT04564157· 3. fázis· Fundación GECP· Forrás
Fut, nem toboroz
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963· 3. fázis· AstraZeneca· Forrás
Toboroz
Randomised Evaluation of COVID-19 Therapy
NCT04381936· 3. fázis· University of Oxford· Forrás
Showing 50 of 55.